Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study

Background: Sorafenib is the currently recommended therapy in patients with advanced hepatocellular carcinoma (HCC). Among the several biomarkers available for the evaluation of the therapeutic response and prognosis, there is perfusion magnetic resonance imaging (p-MRI) that, through measurement of...

Full description

Bibliographic Details
Main Author: Campos,Marta (author)
Other Authors: Candelária,Isabel (author), Papanikolaou,Nickolas (author), Simão,Adélia (author), Ferreira,Carlos (author), Manikis,Georgios C. (author), Caseiro-Alves,Filipe (author)
Format: article
Language:eng
Published: 2019
Subjects:
Hepatocellular carcinoma
Sorafenib
Angiogenesis
Magnetic resonance imaging perfusion
ktrans
Tumor markers
Online Access:http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452019000400006
Country:Portugal
Oai:oai:scielo:S2341-45452019000400006

Internet

http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452019000400006

Similar Items